Author

Yoshikazu Kuboi

Observed names: Y Kuboi, Y. Kuboi, YOSHIKAZU KUBOI, 久保井良和

Observed institutions: Jikei University School of Medicine, Tokyo University of Agriculture, KAN Research Institute, Eisai (Japan)

ORCID: 0000-0002-0782-565X

Observed ORCID: 0000-0002-0782-565X

OpenAlex ID: A5044519948

Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease

2009 · Miyuki Nishimura, Yoshikazu Kuboi, et al. · Annals of the New York Academy of Sciences · 111

Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases

2020 · Yoshiya Tanaka, Kana Hoshino-Negishi, et al. · ImmunoTargets and Therapy · 41

PDF

Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease

2018 · Masayoshi Ohkuro, Jun-Dal Kim, et al. · Nature Communications · 41

PDF

Role of Anti‐Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis

2018 · Kana Hoshino‐Negishi, Masayoshi Ohkuro, et al. · Arthritis & Rheumatology · 34

Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead

2009 · H. Du, T. Matsushima, et al. · Bioorganic & Medicinal Chemistry Letters · 28

Blockade of the fractalkine–CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes

2019 · Yoshikazu Kuboi, Miyuki Nishimura, et al. · International Immunology · 27

Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX 3 CL 1/ CX 3 CR 1 Pathway in Experimental Mouse Models of Systemic Sclerosis

2019 · Vu H. Luong, Akira Utsunomiya, et al. · Arthritis & Rheumatology · 23

Characterization of 5′-flanking region of human aggrecanase-1 (ADAMTS4) gene

2000 · Yoshiharu Mizui, Kazuto Yamazaki, et al. · Molecular Biology Reports · 23

Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice

2021 · Satoshi Mizutani, Junko Nishio, et al. · Pharmaceuticals · 22

PDF

Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model

2022 · Hidetoshi Ishigooka, Haruki Katsumata, et al. · Transplantation · 21

E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis

2017 · Hisashi Wakita, Tatsuya Yanagawa, et al. · Molecular Pharmacology · 21

PDF

Blockade of the fractalkine–CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes

2019 · Yoshikazu Kuboi, Miyuki Nishimura, et al. · International Immunology · 20

PDF

Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time

2019 · Sotaro Motoi, Hiroko Toyoda, et al. · International Journal of Molecular Sciences · 19

PDF

E6201, a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase-1 and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase-1: In Vivo Effects on Cutaneous Inflammatory Responses by Topical Administration

2010 · Kenzo Muramoto, Masaki Goto, et al. · Journal of Pharmacology and Experimental Therapeutics · 19

K1115 A, a New Anthraquinone Derivative that Inhibits the Binding of Activator Protein-1(AP-1) to its Recognition Sites. I. Biological Activities.

1998 · MASAKI GOTO, MASA-AKI MASEGI, et al. · The Journal of Antibiotics · 15

PDF

Cloning of Rabbit TR4 and Its Bone Cell-Specific Activity to Suppress Estrogen Receptor-Mediated Transactivation

1998 · Hideyuki Harada, Yoshikazu Kuboi, et al. · Endocrinology · 15

Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis

2023 · Yoshikazu Kuboi, Yuta Suzuki, et al. · Molecular Therapy — Nucleic Acids · 12

Rationale for and clinical development of anti-fractalkine antibody in rheumatic diseases

2020 · Sei Muraoka, Junko Nishio, et al. · Expert Opinion on Biological Therapy · 11

The Fractalkine‐CX3CR1 Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival

2022 · Yoshikazu Kuboi, Yukiko Kuroda, et al. · JBMR Plus · 9

PDF

1017 PSMA-E7766 ADC: harnessing targeted delivery of STING agonists for anti-tumor activity in prostate cancer

2024 · Brian Drozdowski, Kenzo Arai, et al. · Journal for ImmunoTherapy of Cancer · 4

Effects of CX3CL1 inhibition on murine bleomycin-induced interstitial pneumonia

2020 · Soichi Yamada, Shion Miyoshi, et al. · European Journal of Inflammation · 2

PDF

LB1141 Anti-mouse CX3CL1 monoclonal antibody therapy in mouse models of systemic sclerosis

2019 · M. Hasegawa, V.H. Luong, et al. · Journal of Investigative Dermatology · 2

THU0053 Anti-fractalkine monoclonal antibody ameliorates joint destruction in collagen-induced arthritis model by inhibition of osteoclast precursor cell survival and migration

2018 · Y. Kuboi, K. Hoshino-Negishi, et al. · Annals of the Rheumatic Diseases · 1

PDF

848 Blockade of CX3CL1-CX3CR1 pathway attenuates skin inflammation, fibrosis, and vascular injury in experimental mouse models of systemic sclerosis

2018 · L. Vu Huy, T. Chino, et al. · Journal of Investigative Dermatology · 1

Anti-CX3CL1 monoclonal antibody: A promising therapy for systemic sclerosis

2016 · Vu H. Luong, Takenao Chino, et al. · Journal of Dermatological Science · 1

Works count: 32

Citation count: 523

H-index: 15

I10-index: 18